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Aims. Hyperlipidaemiamodel animals have been used to elucidate the role ofChlamydia pneumoniae (Cpn) infection in atheroscle-
rosis. The aims of this study were to investigate the proatherogenic effect of multiple Cpn infections in ApoB100only/LDLR−/−
mice which based on lipid profile can be regarded as the most suitable mouse model of human hypercholesterolemia and to
compare the lesion development to that in a major atherosclerosis model ApoE−/− mice. Methods and Results. Aorta samples of
ApoB100only/LDLR−/− mice infected three times with Cpn were subjected to morphometric analyses. Morphometric evaluation
disclosed that Cpn infections exacerbated atherosclerosis development in the aortic root and descending aorta of the mice fed with
normal diet. Viable Cpn was detected in the ascending aorta by RT-PCR. Chlamydial 16SrRNA expression showed the presence
of viable Cpn in the aorta of infected animals. A similar rate of acceleration of atherosclerosis was observed when the infection
protocol was applied in ApoB100only/LDLR−/− and in ApoE−/− mice. Conclusion. Similar to ApoE−/− mice, ApoB100only/LDLR−/−
mice with more human-relevant serum lipoprotein composition develop increased atherosclerosis after Cpn infections; thus this
mouse strain can be used as a model of infection-related atherosclerosis enhancement and can provide further evidence for the
proatherogenic influence of Cpn in mice.
1. Introduction
Atherosclerosis is one of the most frequent causes of death in
the world [1]. There are several well-known atherosclerosis
risk factors, such as diabetes mellitus, smoking, hyperten-
sion, hyperlipidaemia, hypercholesterolemia, and abdomi-
nal obesity [2, 3]. The knowledge about the contributory
mechanisms is incomplete [4]. Atherosclerosis begins in the
early childhood [5] and has been characterized as a chronic
inflammatory disease in which both innate and adaptive
immune responses play a role [6]. The damage to the endo-
thelium of the arteries is the primary cause of initiation of
the development of atherosclerosis. High plasma low-density
lipoprotein (LDL) cholesterol concentrations, especially oxi-
dized LDL, contribute to the formation of the atherosclerotic
lesions [7, 8].
Several infectious agents have been associated with the
risk of atherosclerosis [9–12]. The infections and the accom-
panying inflammatory response damage the endothelial cells
and also stimulate monocytes to secrete proinflammatory
cytokines. Numerous studies have demonstrated an associ-
ation between Chlamydia pneumoniae (Cpn) infection and
atherosclerosis [12–14].Cpn infection is ubiquitous, with 50%
of individuals being seropositive by 20 years of age and
approximately 80% in the elderly [13, 15]. Chronic-persistent
infections and reinfections are frequent which may con-
tribute through the induced inflammation to atherosclerosis
[16]. The prevalence of antibodies ranges from 60 to 80%
among patients with cardiovascular diseases [17, 18]. Animal
models that help to clarify the pathogenic steps and causal-
ities in atherosclerosis play an important role in the current
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search for new therapeutics beyond the lipid-lowering drugs.
Normal mice do not develop atherosclerosis and it requires
long-term feeding of a high-fat diet to induce atherogenesis.
However, there are well-established genetically modified
inbred mouse lines that allow the investigation of atheroscle-
rosis development in mouse models. The most frequently
used were ApoE-deficient (ApoE−/−), LDL receptor-deficient
(LDLR−/−), and human apoB100 transgenic mice which
display marked atherogenesis throughout their arterial tree
especially when fedwith atherogenic diet [19, 20]. In ApoE−/−
mice, atherosclerosis develops spontaneously. However, the
lipid profile in these mice is distinct from that seen in most
humans with atherosclerosis; that is, apolipoprotein (apo)
B48-containing LDL plasma level is high instead of apoB100
containing LDL level as in the case of humans with hyper-
cholesterolemia [21, 22]. The mouse strain ApoB100only
(ApoB100/100)/LDLR−/− carries an apoB gene with a mutation
preventing the expression of apoB48, the truncated form of
apoB, similar to humans where no apoB editing takes place
in the liver [21, 23]. LDLR deficiency prevents the uptake of
apoB100 containing LDL in tissues resulting in high plasma
levels of apoB100-containing cholesterol-rich LDL. The cre-
ating authors of this mouse strain described these mice as
an authentic model of human familial hypercholesterolemia
[21].
Inmice, intranasalCpn infection causes lower respiratory
tract disease similar to that seen in humans with Cpn
infection. The infection is followed by dissemination of
bacteria [24] and the chlamydial DNA can be detected in
the circulation of mice [25]. Most frequently, acceleration
of atherosclerosis was studied after repeated Cpn infections
which simulated chronic Cpn infection of humans in asso-
ciation with diet-induced hyperlipidaemia in C57Bl/6J [26],
LDLR−/− [27], orApoE−/− [28]mice andmostly found accele-
rated lesion development. ApoB100only/LDLR−/− mice have
not been used as a model for the investigation of the effect of
Cpn infection on the atherosclerosis progression.
Our aim was to examine how repeated Cpn infection
influences the atherosclerotic lesion development in this,
based on lipid profile, most suitable mouse model of human
hypercholesterolemia and atherosclerosis. We compared the
extent of atherosclerosis in this model with that seen in the
most frequently utilized ApoE−/− mouse strain.
2. Methods
2.1. Chlamydia pneumoniae. Chlamydia pneumoniae,
CWL029 strain from American Types Culture Collection
(ATCC), was used. Cpn was propagated in HEp-2 cells
(ATCC), as described earlier [29]. The partially purified and
concentrated elementary bodies (EBs) were aliquoted in
sucrose-phosphate-glutamic acid buffer (SPG) and stored
at −80∘C until use. Chlamydia was quantitated by indirect
immunofluorescent method applying anti-chlamydia lipo-
polysaccharide monoclonal antibody (AbD Serotec, Oxford,
United Kingdom) and fluorescein isothiocyanate- (FITC-)
labelled anti-mouse IgG (Sigma-Aldrich, St. Louis, MO) as
described earlier [30]. The number of infectious bacteria in
the Cpn stock used for inoculation of mice was expressed as
inclusion-forming units (IFU)/ml.
2.2. Mouse Strains. ApoB100only/LDL−/− (B6.129S-
Ldlrtm1HerApobtm2Sgy/J) mice at 8-9 or 14-15 weeks of age
and ApoE-deficient (ApoE−/−, B6.129P2-Apoetm1Unc/J) mice
at 14-15 weeks of age were involved in our studies. B6.129S-
Ldlrtm1HerApobtm2Sgy/J breeding pairs purchased from the
Jackson Laboratory (Bar Harbor, ME, USA) and B6.129P2-
Apoetm1Unc/J breeding pairs purchased from Charles River
Laboratories (Sulzfeld, Germany) were housed and bred
under standard conditions. Considering that numerous
atherosclerosis-related studies used female mice [31–34],
furthermore it was shown that female mice of both mouse
strains develop atherosclerosis, with no gender-related
difference in ApoE−/− mice and with less extensive lesions
in female than in male ApoB100only/LDLR−/− mice [21, 23];
we chose to work with female mice which were available in
sufficient quantity in our breeding colony.
The mice were kept on normal rodent regular chow
(VRF1, Altromin GmbH & Co. KG, Lage, Germany) or high-
fat/high-cholesterol diet containing 21% milkfat and 1.25%
cholesterol manufactured by Altromin GmbH & Co. KG
according to Teklad custom diet formula TD.19121, [compo-
sition, g/Kg: casein high protein 195.0, DL-methionine 3.0,
sucrose 341.46, corn starch 150.0, anhydrous milkfat 210.0,
cholesterol 12.5, cellulose (fiber) 39.0, mineral mix, AIN-76
(170915) 35.0, calcium carbonate CaCO3 4.0, vitamin mix,
Teklad (40060) 10.0, ethoxyquin (antioxidant) 0.04] for 12
weeks after the first infection. All experiments were approved
by the AnimalWelfare Committee of theUniversity of Szeged
and conform to the Directive 2010/63/EU of the European
Parliament (Permit Number: III./2187/2015.).
2.3. Infection with Cpn. Mice were intranasally infected with
Cpn; 2 × 105 IFU of Cpn in 20𝜇l PBS were administered
intranasally three times with 2-week intervals under mild
anaesthesia by intraperitoneal injection of 100mg/kg sodium
pentobarbital. One week after each infection and at the end of
the experiment at week 12, plasma samples with heparinised
capillaries (Natelson blood collecting tubes, Fisher Scientific,
Pittsburg, PA, USA) were harvested from the retroorbital
plexus under anaesthesia as described above. For RNA
detection in the aorta tissue additional groups of mice were
infected once and sacrificed 1 and 4 weeks after single
infection and 5 weeks after the third infection. The control
animals were left uninfected
2.4. Mouse Tissue Preparation and Quantification of Athero-
sclerosis. Twelve weeks after the first infection with Cpn the
mice were sacrificed. In deep pentobarbital sodium anaesthe-
sia (i.p. injection of 400mg/kg pentobarbital sodium) hearts
and aortas were perfusion-fixed using 10% buffered formalin
administered through the left ventricle. The adequacy of
anaesthesia was assessed by pedal withdrawal reflex in hind
limbs; mice displaying no locomotor activity were processed.
After formalin-perfusion, the upper part of the heart and the
descending aorta were dissected. Aortic sinus samples were
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also collected for RNA extraction frommice anaesthetized as
described above. The basis of the heart was separated from
the aorta which was dissected until the iliac bifurcation. The
upper part of the hearts was embedded in paraffin and sec-
tioned for morphometric analyses according to the method
described by Paigen et al. [35]. From the end of the aortic
sinus 10 𝜇m sections were prepared until the point where
the valve cusps disappeared and stained with hematoxylin
eosin. Images of aortic root sections (8 sections/mouse, every
third sections) were acquired with a light microscope (Leitz
Optical microscope) and Olympus C-7070 digital compact
camera. Percentage length of the plaque-covered perimeter
of aorta lumen and percentage of aorta lumen area occupied
by plaque were analysed with JMicroVision software. The
aortic arch and the adjoining descending aorta were cleared
from adjacent tissue and were opened longitudinally. The
aortas were laid flat on black plastic surface and pictures of
the longitudinally opened vessels were taken applying the
same illumination, magnification, and focal distance using a
CMOS camera (DCM 510; pixel size: 2.2𝜇m × 2.2 𝜇m, 2592 ×
1944 pixels; 5 Mpixel; Hangzhou Scopetek Opto-Electric Co.,
Ltd., Hangzhou, Zheijang, China) and the ScopePhoto soft-
ware (Hangzhou Scopetek Opto-Electric Co., Ltd.) attached
to a stereomicroscope (Alpha STO 44, Elektro-Optika Kft.,
E´rd, Hungary). The digital image of the luminal surface was
evaluated for the extent of atherosclerosis by tracing and
measuring the plaque area and the total luminal surface using
JMicroVision software. The percentage of the luminal area
covered by plaque was calculated for each aorta sample.
2.5. RNA Extraction and Quantitative Real Time-PCR. Aorta
sinus with aortic arch for RNA extraction was collected from
mice (in deep pentobarbital sodium anaesthesia as described
in the previous paragraph) at the indicated time points after
Cpn inoculation for one time or three times and pools of
3 samples at each time points were snap-frozen in liquid
nitrogen. Aorta samples from noninfected mice were also
dissected parallel with the samples collected one week after
one infection.
Total RNA was isolated from the pooled aorta samples
with RNA extraction kit (Nucleospin RNAXS kit, Macherey-
Nagel GmbH, Du¨ren, Germany). Concentration and purity
(OD260/280) of RNAwas determined by spectrophotometry.
The extracted RNA was treated with DNaseI (Sigma, St.
Louis, MO, USA). Complementary DNA (cDNA) was syn-
thetized from 1 𝜇g DNase-treated RNA with qScript cDNA
Supermix synthesis kit (Quanta Biosciences, Gaithersburg,
MD, USA). RNA and cDNA were stored at −80∘C until use.
By using cDNA as template qRT-PCR was performed
with PerfeCTa SYBR Green Supermix (Quanta) in CFX96
Real Time C1000 Thermal Cycler (BioRad, Hercules, CA,
USA). All experiments involved control reactions containing
distilled water as template. Chlamydia 16SrRNA and mouse
𝛽-actin sequences were amplified. The sequences of primers
used for RT-PCR were the following: Cpn 16S rRNA: 5󸀠-
GGCGAAGGCGCTTTTCTAA-3󸀠, 5󸀠-CCAGGGTATCTA-
ATCCTGTTTGCT-3󸀠 [36]; mouse 𝛽-actin: 5󸀠-TGGAAT-
CCTGTGGCATCCATGAAA-3󸀠, 5󸀠-TAAAACGCAGCT-
CAGTAACAGTCCG-3󸀠 [37].
A BLAST search was performed to check the specificity
of the product target sequence of the primer sets. The
primers were synthesized by Integrated DNA Technologies
Inc. (Montreal, Quebec, Canada). The PCR cycles consisted
of a 3min denaturation at 95∘C followed by 55 cycles each
of 10 s of denaturation at 94∘C, 10 s of annealing at 60∘C
and 10 s of extension at 72∘C. The specificity of amplification
was confirmed by carrying out a melting curve analysis. The
sensitivity of amplification was controlled using standard as
described earlier [38]. Amplicon standard was generated by
amplifying Cpn cDNA with 16S rRNA primers; amplicons
were purified with the PCR Clean-Up Kit (GeneElute PCR
Clean-Up Kit, Sigma-Aldrich); the DNA concentration was
measuredwithNanoDrop 1000 Spectrophotometer.The copy
number was calculated using the following formula: copy
number/𝜇l = [6.022 × 1023 (molecules/mole) × DNA con-
centration (g/𝜇l)]/(number of bases pairs × 660 daltons); and
standard curve were generated from 10-fold serial dilutions
of the amplicon (from 1000,000 to 1 copies). qPCR analysis
of the dilution series showed that the sensitivity threshold of
our method was ten 16SrRNA copies.
2.6. ELISA for Detection of Cpn-Specific Antibodies. Plasma
samples of mice collected one week after each infection and
at the end of the experiment were tested in duplicate for Cpn-
specific IgG, IgM, and IgA by an in-house developed ELISA
test as described earlier [25], where NP-40 treated partially
purified Cpn and similarly treated Hep-2 mock preparation
were used as antigens. Briefly, NUNCMaxisorp ELISA plates
were coated with Cpn and mock antigen (0.625 𝜇g protein in
50 𝜇l PBS/well), respectively, overnight at 4∘C. Blocking was
done with 1% skim milk in PBS with 0.05% TWEEN 20 for
1 h.The serum samples were diluted in 0.4% skimmilk in PBS
with 0.05% TWEEN 20.
Mouse IgG, IgM, and IgA were detected with HRP-anti-
mouse IgG (Jackson ImmunoResearch Laboratories West
Grove, PA, USA), 𝛼-mouse IgA-HRP (Sigma), and anti-
mouse IgM 𝜇-chain (ab97260, Abcam, Cambridge, UK)
secondary antibodies, respectively. Optical densities (OD-
s) detected on Cpn antigen were corrected with OD values
measured on the control antigen. Cpn-specific IgG antibody
titres were determined by testing serial 2-fold dilutions of
the serum samples on Cpn and control ELISA antigen, and
reciprocal of the dilution producing OD ≥ 0.1 after correction
with OD values measured on control antigen was regarded as
titre. Geometric mean of titres of individual serum samples
was calculated. For determination of Cpn-specific IgM and
IgA levels serum samples were tested at 1 : 50 dilution and
determined as the measured and corrected OD values.
2.7. Serum Lipoprotein Analysis. Levels of total cholesterol,
triglycerides, high-density lipoprotein (HDL), and LDL-
cholesterol were determined in plasma samples of mice
through a service from the Department of Laboratory Medi-
cine, University of Szeged, Hungary.
2.8. Statistical Analysis. Data are expressed as mean ± SD.
Independent-samples 𝑡-test was used with SigmaPlot for
Windows Version 11.0 software. A 𝑃 value of less than
4 BioMed Research International
0.05 was considered to indicate statistically significant differ-
ence.
3. Results
3.1. Infection of ApoB100only/LDLR−/− Mice with Cpn. Mice
infected 3 times withCpn showedmild symptoms of a disease
as ruffled fur and moderate food consumption, especially
during the first week after the first infection. At the time of
the first infection half of the mice were given a high-fat/high-
cholesterol diet the other half were kept on normal rodent
chow. Noninfected mice were kept under similar conditions.
All infected mice produced Cpn-specific antibodies which
were not seen in the noninfected mice. Normal and high-
fat/high-cholesterol diet-fed mice produced similar level of
Cpn-specific IgG antibodies (OD 0.36–0.4 at dilution 1 : 100).
3.2. Repeated Cpn Infection Aggravates Atherosclerosis Devel-
opment in the Aorta Sinus and in the Descending Aorta
of ApoB100only/LDLR−/− Mice Kept on Normal Diet. The
mice received the first Cpn infection at the age of 8-9
weeks; uninfected mice with same age served as controls.
Fed with an atherogenic diet very similar pathology was
observed in the aorta sinus of the mice that received three
chlamydia infections and in those remaining uninfected.The
quantitative evaluation did not disclose significant difference
in the length of the plaque-covered perimeter of the lumen
(Figure 1(a)) nor in the size of the plaque-occupied area in the
aorta lumen (Figure 1(b)). The aorta sections of the normal
diet-fed noninfected animals demonstrated very early-stage
and small extent of atherosclerosis with a single layer of
foam cells. However, in the aorta sections of repeatedly Cpn-
infectedmice, we observed a significant increase in the length
of the plaque-covered perimeter of the lumen (𝑃 < 0.05)
(Figure 1(a)) and in the size of the plaque-occupied area in
the aorta lumen (𝑃 < 0.05) (Figure 1(b)) compared with that
in the noninfected counterpart in normal diet-fed group.
On the luminal surface of the longitudinally opened
descending aorta well discernible plaques could be observed.
Small areas corresponding to atherosclerotic alteration were
seen in the case of the aorta of the noninfected animals
fed with normal diet. The atherosclerosis-affected areas were
measured significantly larger in the descending aorta of
the infected animals. In the high-fat/high-cholesterol diet-
fed animals, significantly increased plaque-covered spots
were visible compared to that in the normal diet-fed mice;
however, the infection did not enhance the lesion formation
in this part of the aorta (Figure 1(c)).
3.3. Viable Cpn Was Detectable in the Aorta of ApoB100only/
LDLR−/− Mice. Figure 2(a) shows that the persistence of the
bacterium was tested early, that is, one week after the first
infection and again four weeks after single infection and
at 9-week and 12-week time points after three chlamydial
infections by RT-PCR. An equal amount of RNA purified
from pooled ascending aorta samples of mice was DNase-
treated and then reverse-transcribed and mouse 𝛽-actin as
housekeeping gene was amplified from all samples. One
and four weeks after single inoculation the expression of
chlamydial 16SrRNA was detectable (Figure 2(b)) with a ∼
1000-fold lower relative expression level at four weeks than
at 1-week time point (Figure 2(c)). Five weeks after the third
infection one aorta sample of 2 showed metabolically active
Cpn in the aorta and the relative expression level was similar
to that after single infection at 4 weeks (Figure 2(c)). At later
time point, our test was not able to detect chlamydial gene
expression.
3.4. Infection of ApoB100only/LDLR−/− and ApoE−/− Mice
with Cpn Induces Similar Kinetics of Antibody Production.
Based on the above results, we aimed at performing a
comparative experiment by applying our infection protocol
both in ApoB100only/LDLR−/− and in ApoE−/− mice (14-15
weeks of age) while keeping them on a nonatherogenic diet.
The humoral immune response induced by the infections
was compared by measuring the titre of Cpn-specific IgG
antibodies (Figure 3(a)) and the level of IgM (Figure 3(b))
and IgA (Figure 3(c)) antibodies one week after all three
infections and at the end of the experiment. The level of anti-
body response did not differ significantly in the two mouse
strains. The IgA level tended to be lower in ApoE−/− mice
(Figure 3(c)); however, the differencewas not significant. Two
independent experiments gave similar results.
3.5. The Extent of Atherosclerosis Is Similarly Increased in
the Aorta of Cpn-Infected and Normal Diet-Fed ApoB100only/
LDLR−/− andApoE−/−Mice. In normal chow-fedApoB100only/
LDLR−/− mice at the age of 24-25 weeks the lesions consisted
of mainly single or multiple layers of macrophage foam
cells but some more advanced plaques with cholesterol
crystals and necrotic core were also seen. In ApoE−/− mice
at same age more numerous advanced lesions with necrotic
core and cholesterol cleft were found. In Cpn-infected
ApoB100only/LDLR−/− mice larger advanced plaques and in
infected ApoE−/− mice more plaques with necrotic core and
accumulated cholesterol crystals appeared. Representative
sections from the experimental groups are shown in Fig-
ure 4(a).
The measurements proved that in ApoE−/− mice the
atherosclerosis was more pronounced than in ApoB100only/
LDLR−/− mice. The difference was seen in respect of the
size of plaque-occupied lumen area in the aortic sinus
(Figure 4(b)) and the length of the plaque-covered aorta
surface in the lumen (Figure 4(c)). Lesions in the descending
aorta also were larger in ApoE−/−mice than in ApoB100only/
LDLR−/− mice (Figures 4(d) and 4(e)). When the effect of
Cpn infection was analysed, significant enhancement in the
measured values was found. The plaque-covered perimeter
of the lumen in the aorta sinus sections (Figure 4(b)), the
plaque-occupied lumen area (Figure 4(c)), and the plaque
size in the descending aorta (Figure 4(e)) increased 2.08-fold
(𝑃 = 0.035), 1.7-fold (𝑃 = 0.004), and 2.5-fold (𝑃 = 0.001),
respectively, in ApoB100only/LDLR−/− and 2.04-fold (𝑃 =
0.019), 1.32-fold (𝑃 = 0.026), and 2.56-fold (𝑃 = 0.002),
respectively, in ApoE−/− mice.
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Figure 1: Morphometric analyses of atherosclerotic plaques in ApoB100only/LDLR−/− mice. (a) Measurements for the length of the aortic
luminal surface (perimeter) covered by plaque (PAP/AP × 100); (b) percentage of aortic lumen area occupied by plaques (PLA/LA × 100)
in 8 cross sections of aortic root from each ApoB100only/LDLR−/− mouse in groups kept on normal diet without Cpn infection (number
of mice (𝑁) = 6) or infected with Cpn 3 times (𝑁 = 8) or on high-fat/high-cholesterol diet for 12 weeks without Cpn infection (𝑁 = 6)
or infected with Cpn 3 times (𝑁 = 8). Average percentage values from individual mice and mean percentages in groups are shown. PAP:
plaque-covered aorta perimeter; AP: aorta perimeter; PLA: plaque-occupied lumen area; LA: aorta lumen area. (c) Plaque size was measured
in the longitudinally opened descending aorta of each ApoB100only/LDLR−/− mouse in groups kept on normal or high-fat/high-cholesterol
diet for 12 weeks without Cpn infection or infected with Cpn 3 times. The percentage of total aorta area covered by plaques was calculated.
Data show the results of one of two independent experiments. For comparison of groups independent-samples 𝑡-test was used, ∗𝑃 < 0.05.
ND: normal diet; HFD: high-fat/high-cholesterol diet; 3x: three intranasal Cpn infections.
3.6. Plasma Lipid Levels in ApoB100only/LDLR−/− and
ApoE−/− Mice. Plasma samples of mice were tested for lipid
levels. At each tested time point irrespective of the infection
status ApoE−/− mice carried a higher level of total choles-
terol than the ApoB100only/LDLR−/− mice (Figure 5(a)). In
the plasma of uninfected ApoB100only/LDLR−/− mice the
triglyceride concentration was elevated compared to that in
ApoE−/− mice (Figure 5(b)). Infection one or two times did
not cause increase in triglyceride level, but the third Cpn
inoculation resulted in a significant elevation (𝑃 = 0.001) in
ApoE−/− mice. In ApoB100only/LDLR−/− mice no infection-
related change in triglyceride level was obvious (Figure 5(b)).
Plasma concentration of LDL was higher in ApoE−/− mice
than in ApoB100only/LDLR−/−mice (Figure 5(c)). Infection-
related significant increase in LDL level was associated
with the first infection in ApoB100only/LDLR−/− mice only
(𝑃 = 0.04). HDL plasma concentration was generally
higher in ApoB100only/LDLR−/− mice than in ApoE−/−
mice and in these mice the concentration decreased by
the end of the observation period but remained high in
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Figure 2: Chlamydia RNA in the aorta tissues. (a) Experimental design for Cpn infection of ApoB100only/LDLR−/− mice and 16SrRNA
transcript detection in pooled aorta samples (two pools of 3 aortas from 6 mice) of one time (1x Cpn) and 3 times (3x Cpn) Cpn-infected
and noninfected mice (“+”: aorta samples tested positive; “−”: aorta samples tested negative for expression of 16SrRNA by qRT-PCR). ((b)A)
Identification of the RT-PCR-amplifiedCpn 16SrRNA cDNA in the aorta ofCpn-infected ApoB100only/LDLR−/−mice.Melt curves showCpn
16SrRNA amplicons in (1) Cpn-infectedMcCoy cells (positive control); (2), (3) in aorta samples tested 1 week after single Cpn infection; (4) in
aorta samples 5 weeks after third Cpn infection, (5), (6) in aorta samples 4 weeks after a single Cpn infection; ((b)B) 𝛽-actin amplicons in all
tested aorta samples and Cpn-infected McCoy cells. (c) Expression of Cpn 16SrRNA normalized to the expression level of mouse 𝛽-actin at 1
week after single Cpn infection was set as 1 and relative mouse 𝛽-actin-normalized Cpn 16SrRNA expression level in all pooled aorta samples
giving positive 16SrRNA signal was calculated. The measurements were repeated two times with the same results.
ApoB100only/LDLR−/− mice (Figure 5(d)). No infection-
associated change in HDL level was detected.
4. Discussion
ApoE−/−mice arewidely used as animalmodels of atheroscle-
rosis; however, the lipoprotein metabolism of this mouse
strain is different from that in humans with hypercholes-
terolemia. ApoE−/− mice accumulate in their plasma large
quantities of ApoB48 containing lipoprotein of the very
low-density lipoprotein (VLDL) class while humans with
atherosclerosis almost always have high level of cholesterol-
rich LDL containing ApoB100 [23, 31]. Many publications
investigating the relation of Cpn with atherosclerosis have
used this model to disclose the nature of the associa-
tion between infection with this pathogen and initiation
and/or acceleration of atherosclerosis [28, 39–42]. It has
been suggested that Cpn infection exacerbates atheroscle-
rosis in conjunction with hyperlipidaemia; however, ApoE
deficiency might influence the immune response to this
pathogen and provides increased resistance to vascular infec-
tion [41]. We aimed at examining the influence of repeated
Cpn infection on the formation of atherosclerotic plaques
in ApoB100only/LDLR−/− mouse strain another model for
lipoprotein abnormalities which can be regarded as the most
faithful model of human familial hypercholesterolemia [21].
ApoB100only/LDLR−/− mouse strain was created by
genetic modification, so that majority of their plasma choles-
terol is in the LDL class with ApoB100 and develops athero-
sclerosis on low-fat, chow diet. First, we wanted to establish
that ApoB100only/LDLR−/− mice can serve as a model for
investigating the role of Cpn in atherosclerosis. Therefore
groups of mice were fed with a normal or high-fat/high-
cholesterol diet and were repeatedly infected with Cpn or left
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Figure 3: Cpn-specific antibodies in the mice.The serum antibody levels were measured in ApoB100only/LDLR−/− and ApoE−/− mice 1 week
after first (1x), second (2x), third (3x) Cpn infection and at the end of the experiment (week 12) by an in-house ELISA test with Cpn antigen.
(a) Geometric mean (GM) of IgG titres, reciprocal of dilutions producing OD ≥ 0.1 is shown. (b) For detection of Cpn-specific IgM and (c)
IgA level in the sera 1 : 50 dilutions of serum samples (ApoB100only/LDLR−/−:𝑁 = 7, ApoE−/− mice:𝑁 = 8) were tested with the ELISA test.
OD values and standard deviations (SD) are shown. Data represent the results of one of two independent experiments.
uninfected, and development of atherosclerosis was followed.
As our experiments showed, in ApoB100only/LDLR−/− mice
which were fed with normal diet repeated three Cpn infec-
tions resulted in an enhanced atherosclerosis development
in the aortic sinus and the descending aorta. High-fat/high-
cholesterol diet-induced enhanced atherosclerosis was not
exacerbated by Cpn infections. Thus all further experiments
were done with mice kept on normal diet. As it is said
that Cpn acts in cooperation with hyperlipidaemia it seems
that the effect of hyperlipidaemia in ApoB100only/LDLR−/−
mice can be aggravated by Cpn infection but Cpn does
not exacerbate atherosclerosis further in the presence of
high-fat/high-cholesterol diet [43–45]. Nevertheless, the bac-
terium influenced the course of atherosclerosis development
indicating that ApoB100only/LDLR−/− mice are suitable for
further research. Our results are consistent with findings
of Moazed et al. who described atherosclerosis-accelerating
effect of Cpn infection in ApoE−/− mice eating regular chow
diet [44]. However, atherosclerosis was also exacerbated in
ApoE−/− mice kept on high-fat diet by single or 3 repeated
Cpn infections [39, 46].
We hypothesized that, based on the genetic difference
between ApoB100only/LDLR−/− and ApoE−/− mice, features
that characterize Cpn infection or atherosclerosis may also
differ, and therefore we compared the effects of the bacterium
in these mouse strains. In our infection model the successful
infection was demonstrated by detecting Cpn-specific IgG,
IgA, and IgM antibodies in the mice throughout the course
of the experiment and at the time of sacrifice. When IgG
antibody level was compared in ApoB100only/LDLR−/− and
ApoE−/−mice, no significant difference was observed. Nazzal
et al. [41] reported that ApoE−/− mice produced more Cpn-
specific antibodies than wild-type mice which was attributed
toApoEdeficiency.Our results donot support this suggestion
considering that in ApoB100only/LDLR−/− mice repeated
Cpn infection led to high level of antibody production
without the contribution of ApoE deficiency.
Not only was antibody response the sign of infection,
but we were able to detect metabolically active Cpn in the
aorta samples for nine weeks after the first infection. Previous
studies demonstrated the presence of Cpn in the aorta of
repeatedly infected ApoE−/− mice by isolating the bacterium
early two weeks after infection. Furthermore, bacterial DNA
was amplified by PCR at later time points [47]. As reviewed by
Campbell and Rosenfeld [48] several lines of evidence point
to the ability of Cpn to establish persistent infection in vivo.
Our results provide additional information about persisting
chlamydia as 16SrRNA gene transcripts suggest metabolically
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Figure 4: Comparative quantitative assessment of atherosclerosis in ApoB100only/LDLR−/− and ApoE−/−mice. Atherosclerosis development
was assessed by histological andmorphometric analyses in the aorta sinus and descending aorta of ApoB100only/LDLR−/− and ApoE−/−mice
without and with 3 Cpn infections, 12 weeks after the first infection kept on normal diet. (a) Photo of representative hematoxylin and eosin-
stained cross sections of the noninfected and Cpn-infected ApoB100only/LDLR−/− mice and noninfected and Cpn-infected ApoE−/− mice
(scale bar: 500 𝜇m). Arrows point to atherosclerotic lesions. (b) The percentage length of the aortic luminal surface (perimeter) covered
by atherosclerotic plaque (PAP/AP × 100); (c) percentage of aortic lumen area occupied by atherosclerotic plaques (PLA/LA × 100) in 8
sections of aortic root from noninfected (𝑁 = 6), Cpn-infected (𝑁 = 7) ApoB100only/LDLR−/−, and noninfected (𝑁 = 6) and Cpn-infected
(𝑁 = 8) ApoE−/− mice. Average percentage values from individual mice and mean percentages in groups are shown. (d) In situ microscopic
pictures of en face proximal aorta of noninfected and Cpn-infected ApoB100only/LDLR−/− and ApoE−/− mice, respectively. (e) Plaque size
was measured on the length of the luminal surface of the descending aorta of 6–8 mice, and the percentage of total aorta area covered by
plaques was calculated. Percentage values in individual mice and mean percentages in groups are shown. Data demonstrate the results of
one of two independent experiments. For comparison of groups independent-samples 𝑡-test was used, ∗𝑃 < 0.05. PAP: plaque-covered aorta
perimeter; AP: aorta perimeter; PLA: plaque-occupied lumen area; LA: aorta lumen area; 3x: three intranasal Cpn infections.
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Figure 5: Plasma lipid levels in the mice. Plasma samples of ApoB100only/LDLR−/− and ApoE−/− mice taken at 1 week after the first (1x),
second (2x), and third (3x) Cpn infection and at the end of the experiment (week 12) and from the noninfected control mice at the same
time points were tested for concentration of (a) total cholesterol, (b) triglyceride, (c) LDL, and (d) HDL content. Lipid concentrations are
expressed asmmol/L;mean of valuesmeasured in individualmouse sera (ApoB100only/LDLR−/− noninfected (𝑁 = 6),Cpn-infected (𝑁 = 7),
and ApoE−/− mice noninfected (𝑁 = 6), Cpn-infected (𝑁 = 8)), and standard deviations (SD) are shown; independent-samples 𝑡-test was
used, ∗𝑃 = 0.01. The figure demonstrates the results of one of two independent experiments.
active bacteria not only persisting DNA or antigen late after
repeated infections. Long-term presence of viable chlamydia
in the aorta tissues of some infected mice might contribute to
the atherogenic effect of the infection.
In female ApoE−/− mice we have disclosed more ad-
vanced atherosclerosis than in ApoB100only/LDLR−/− mice
at the same age at the end of the 12-week observation
period. Less pronounced difference was disclosed by Powell-
Braxton et al. [21]. Nevertheless, in ApoE−/− mice, similar
to ApoB100only/LDLR−/− mice, the infection resulted in an
enhanced lesion formation without the need of feeding the
mice with high-fat diet confirming the results with ApoE−/−
mice of Moazed et al. [44].
It has been described that Cpn can cause hepatic fatty
acid imbalance [49] dysregulation of lipid metabolic genes in
the liver [50] and alteredmacrophage cholesterol homeostasis
[51]; however, most of the studies in mice did not detect
major changes in plasma lipid profile after Cpn infection
[34, 39]. Increase in triglyceride concentration after repeated
infection of ApoE−/− mice similarly to our results has been
noted by Rothstein et al. [33]. The reason of increase in
triglyceride level in chronic infection induced by multiple
inoculations in ApoE−/− mice may be the absence of ApoE.
ApoE is known to provide protection against the inflam-
mation induced by bacterial lipopolysaccharide [52] and the
inflammation related change in lipid metabolism [53]. Early
increase of LDL level in ApoB100only/LDLR−/− mice after
primary infection may also be due to the primary infection
caused inflammation [54]. Our findings are concordant
with results of a study by Kontula et al. [55] suggesting a
significant association between chronic infection with Cpn
and increased risk of coronary heart disease in patients with
familial hypercholesterolemia.
5. Conclusion
In the field of infection-related exacerbation of atheroscle-
rosis, the ApoB100only/LDLR−/− mouse strain has not been
utilized. According to our results the infection is followed
by long-lasting vascular infection in this mouse strain con-
tributing to the potential direct effect of the infection in
the vessel wall. As ApoE deficiency may alter the immune
response against Cpn infection compared to wild-type mice,
ApoB100only/LDLR−/− mice might provide additional infor-
mation regarding the immune mechanisms participating in
10 BioMed Research International
the Cpn induced acceleration of atherosclerosis. The results
of our experiments further support the proatherogenic role
of Cpn infection in a model of human familial hypercholes-
terolemia. As repeated Cpn inoculation is able to aggra-
vate lesion development in association with the lipoprotein
abnormalities without feeding high-fat/high-cholesterol diet
to these mice, we suggest using this mouse strain as an alter-
native model to investigate the role of infection in atheroscle-
rosis development.
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